AC102 is tested in patients for the first time
There is still no approved and effective drug for the treatment of acute hearing loss, even though the psychosocial consequences of this disease can be devastating. Since AC102 almost completely reversed hearing loss in animal models, it has the great potential to become a next generation inner ear therapeutic for the causal and specific treatment of acute hearing loss.
AC102 already successfully completed a Phase I clinical trial and showed good tolerability. Currently, AC102 is beeing examined in a phase II clinical study and administered to patients for the first time. In the pan-european two-arm study, the patient group will be administered AC102 once directly into the middle ear, while the comparison group will receive a steroid medication, the current, but unapproved, standard therapy.